Free weekly newsletter

Get the free weekly executive digest

The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New leadership moves, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Leadership Trends

See who's moving and how much in your market

No credit card required Weekly executive digest

Exai Bio Appoints Dave Daly As Chief Executive Officer

PRIVATEJul 24, 2024•almost 2 years ago

Position

Chief Executive Officer

Company

Exai Bio

Dave Daly

Palo AltoBiotechnologySoftwareScience And Engineering

Description

Exai Bio announced the appointment of Dave Daly as Chief Executive Officer. With over 30 years of experience in cancer diagnostics and executive leadership, Daly is poised to lead Exai’s accelerated product development and partnering strategy. Exai’s liquid biopsy platform uses RNA sequencing to identify a novel category of cancer-associated, small non-coding RNAs, termed oncRNAs.

Company Information

Company

Exai Bio

Location

3350 W. BAYSHORE ROAD

Palo Alto, California, United States

About

Exai Bio is a next-generation liquid biopsy company. Our mission is to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized and targeted way, and ultimately cured. The company’s proprietary RNA and artificial intelligence-based liquid biopsy platform delivers clinical insights into cancer biology to enable the earliest, most accurate diagnosis of cancer. Exai Bio was founded with technology from the UCSF laboratory of Dr. Hani Goodarzi, and consists of veteran leaders in the RNA biology, liquid biopsy, and artificial intelligence/machine learning fields from both academia (UCSF, Stanford, MIT) and industry (Bluestar, CareDx, Evidation, Google, 23andMe, Deep Genomics). Exai Bio is supported by leading life sciences and tech investors including Section 32, Casdin Capital, and Two Sigma Ventures, who have been integral to advancing cancer diagnostics, and artificial intelligence and machine learning technologies.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Exai Bio's next move

Learn about Strategic plan

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months